Earlier this week, The US Food and Drug Administration (FDA) granted NeuroRx and Relief Therapeutics an Investigational New Drug (IND) permission to test their investigational therapy, RLF-100, for inhaled use in patients with moderate and severe coronavirus 2019 (COVID-19) in order to prevent progression to respiratory failure. RLF-100 contains Vasoactive Intestinal Polypeptide (VIP), a natural occurring peptide […]
ZURICH — The U.S. Food and Drug Administration has granted NeuroRx Inc Investigational New Drug (IND) permission to test RLF-100 (aviptadil) for inhaled use in patients with moderate and severe COVID-19 to prevent progression to respiratory failure, it and partner Relief Therapeutics Holdings said on Thursday. The clinical trial of the inhaled formulation of RLF-100 […]
The US Food and Drug Administration (FDA) has granted NeuroRx and Relief Therapeutics an Investigational New Drug (IND) permission to test RLF-100 for inhaled use in patients with moderate and severe coronavirus 2019 (COVID-19) in order to prevent progression to respiratory failure. The first phase will commence with patients hospitalized for severe COVID-19 who do not yet […]